title: [Using hepatomaks forte in the treatment of chronic alcoholic hepatitis].
abstract: Installed significantly more pronounced positive effect on clinical manifestations and laboratory indicators of liver in patients with chronic alcoholic hepatitis who received within 4 weeks of basal therapy in conjunction with Gepatomax Forte in comparison with a group of patients with chronic alcoholic hepatitis who received during the same time only basic therapy. Side adverse effects in the group of patients receiving Gepatomax Forte were not registered.
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Linevskiĭ
authors.forename: K Iu
authors.initials: KIu
authors.lastname: Linevskaia
authors.forename: K A
authors.initials: KA
authors.lastname: Voronin
mesh_terms: D000328:Adult; D004338:Drug Combinations; D005260:Female; D006519:Hepatitis, Alcoholic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D054709:Lecithins / Q000008:administration & dosage / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D012838:Silymarin / Q000008:administration & dosage / Q000627:therapeutic use*; D008063:Thioctic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D054709:Lecithins; D012838:Silymarin; D008063:Thioctic Acid